Skip to main content
SpringerLink
Log in

Medical oncology

Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer

  • News & Views
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

In the movement towards individualized treatment regimens, Rothenberg et al. validate XELOX as another available systemic therapy for patients being treated with second-line treatment for metastatic colorectal cancer. This paper adds to a growing body of data in the first-line and second-line setting that confirms the noninferiority of oral fluoropyrimidine-containing regimens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rothenberg, M. et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann. Oncol. 19, 1720–1726 (2008).

    Article  CAS  Google Scholar 

  2. Cassidy, J. et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J. Clin. Oncol. 26, 2006–2012 (2008).

    Article  CAS  Google Scholar 

  3. Ducreux, M. et al. Efficacy and safety findings from a randomized phase III study of capecitabine (X) and oxaliplatin (O) (XELOX) vs infusional 5-FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC) [Abstract]. ASCO Meeting Abstracts 25, 4029 (2007).

    Google Scholar 

  4. Arkenau, H. T. et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J. Clin. Oncol. 26, 5910–5917 (2008).

    Article  CAS  Google Scholar 

  5. Haller, D. G. et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J. Clin. Oncol. 26, 2118–2123 (2008).

    Article  CAS  Google Scholar 

  6. Arkenau, H. et al. Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. Clin. Colorectal Cancer 7, 60–64 (2008).

    Article  CAS  Google Scholar 

  7. Schmoll, H. J. et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J. Clin. Oncol. 25, 102–109 (2007).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA

    Ursina R. Teitelbaum & Daniel G. Haller

Authors
  1. Ursina R. Teitelbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel G. Haller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel G. Haller.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Teitelbaum, U., Haller, D. Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer. Nat Rev Clin Oncol 6, 250–251 (2009). https://doi.org/10.1038/nrclinonc.2009.46

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2009.46

  • Springer Nature Limited

Search

Navigation